Starling Oncology projects FY26 revenue of $650 – 660M and FY26 Adj. EBITDA of $4 – 6M, after 3Q26 revenue of $170M increased 24% YoY and Adj EBITDA reached $3.4M.
STLN · Starling Oncology, Inc. · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Starling Oncology forecasts FY26 revenue of $650 – 660M and Adjusted EBITDA of $4 – 6M; 3Q26 revenue increased 24% YoY to $170M, with Adjusted EBITDA of $3.4M.
Starling Oncology reported third-quarter revenue of $169,767 and net loss of $(15,748), with figures in thousands; Adjusted EBITDA was $3,394. At September 30, 2026, cash was $36,895, and management expected liquidity for at least one year.
Starling Oncology reported third-quarter revenue of $169.8 million, up 24.3% year over year, and Adjusted EBITDA of positive $3.4 million. It updated fiscal-year 2026 revenue guidance to $650 to $660 million and Adjusted EBITDA guidance to $4 to $6 million.